![](/fileadmin/_processed_/csm_AC_Immune-Pipeline_0531719e36.png)
AC Immune and Takeda ink US$2.1bn biobucks deal
Under the US$2.1bn biobucks deal, Pharma giant Takeda gets the globally exclusive right to licence AC Immune SA's active immunisation therapy...
![](/fileadmin/_processed_/csm_Fundus_-_diabetic_retinopathy_c83d88301e.png)
MSD grabs Eyebiotech Ltd for US$1.3bn upfront
With the strategic acquisition,which has been unanimously approved by the EyeBio Board of Directors, MSD will take over Eyebiotech's clinical...
![](/fileadmin/_processed_/csm_Obstructive_Sleep_Apnea_Treatment_Genio_by_Nyxoah_083756dfdb.png)
Nyxoah signs a €37.5m loan with the European Investment Bank
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), located in Mont-Saint-Guibert, Belgium announced that it has signed a €37.5m loan facility agreement with...
![](/fileadmin/_processed_/csm_NOVo_New_434e85ba4f.png)
Obesity: reseachers switch on brown fat cells
The new discovery could herald a revolution in obesity research. If the principle discovered in male mice also applies in humans, therapeutics...
![](/fileadmin/_processed_/csm_tme_eisberg_illu_cxcl12_56348618ca.jpg)
TME Pharma gets FDA Fast Track for Glioblastoma
TME Pharma N.V. with research sites in France and Germany (listed at Euronext Growth Paris: ALTME) is developing novel therapies for treatment of...
![](/fileadmin/_processed_/csm_Iqvia-obesity_pipeline_0680784a7f.png)
AstraZeneca puts step into obesity market
SixPeaks Bio, launched with US$30m in Series A funding led by Versant Ventures, which is known for its build to buy strategy, and announced a...
![](/fileadmin/_processed_/csm_quantro_747ee92cb9.png)
Quantro Therapeutics cashes in milestone payment from Boehringer Ingelheim
Austrian QUANTRO Therapeutics GmbH has reached a key milestone in its three year R&D and licence option collaboration with Boehringer...